✦ LIBER ✦

Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration

✍ Scribed by Luca Laurenti; Michela Tarnani; Laura De Padua; Dimitar G. Efremov; Gina Zini; Mariagrazia Garzia; Nicola Piccirillo; Patrizia Chiusolo; Federica Sorà; Idanna Innocenti; Simona Sica; Giuseppe Leone

Publisher: Springer
Year: 2008
Tongue: English
Weight: 159 KB
Volume: 87
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-008-0527-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison between oral and intravenous

Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome

✍ Luca Laurenti; Laura De Padua; Michela Tarnani; Nicola Piccirillo; Paolo Falcucc 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 159 KB

Amifostine does not reduce the toxicity

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

✍ Francis J. Giles; Gary Guangping Shi; Jorge E. Cortes; Deborah Thomas; Anna R. K 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 189 KB

Combination therapy with fludarabine and

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO